rongliflozin (HEC44616)
/ Sunshine Lake Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 7
Of
7
Go to page
1
May 06, 2026
A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Pyroglutamate Rongliflozin Capsules in Subjects With Mild and Moderate Liver Damage
(clinicaltrials.gov)
- P1 | N=32 | Completed | Sponsor: Sunshine Lake Pharma Co., Ltd. | Recruiting ➔ Completed
Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • AFP
May 01, 2026
A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Rongliflozin in Type 2 Diabetic Subjects With Renal Impairment
(clinicaltrials.gov)
- P1 | N=32 | Completed | Sponsor: Sunshine Lake Pharma Co., Ltd. | Recruiting ➔ Completed
Trial completion • Diabetes • Metabolic Disorders • Renal Disease • Type 2 Diabetes Mellitus
April 12, 2023
ADME Study of [14C]- Rongliflozin in Healthy Male Subjects
(clinicaltrials.gov)
- P1 | N=6 | Completed | Sponsor: Sunshine Lake Pharma Co., Ltd. | Not yet recruiting ➔ Completed
Trial completion
March 01, 2023
Effects of Rifampicin and Probenecid On The Pharmacokinetic Profile Of Rongliflozin In Healthy Subjects
(clinicaltrials.gov)
- P1 | N=28 | Completed | Sponsor: Sunshine Lake Pharma Co., Ltd. | Trial completion date: Aug 2022 ➔ Feb 2023
Trial completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
August 11, 2022
Effects of Rifampicin and Probenecid On The Pharmacokinetic Profile Of Rongliflozin In Healthy Subjects
(clinicaltrials.gov)
- P1 | N=28 | Completed | Sponsor: Sunshine Lake Pharma Co., Ltd.
New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
June 22, 2022
A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Pyroglutamate Rongliflozin Capsules in Subjects With Mild and Moderate Liver Damage
(clinicaltrials.gov)
- P1 | N=32 | Recruiting | Sponsor: Sunshine Lake Pharma Co., Ltd.
New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • AFP
May 16, 2022
A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Rongliflozin in Type 2 Diabetic Subjects With Renal Impairment
(clinicaltrials.gov)
- P1 | N=32 | Recruiting | Sponsor: Sunshine Lake Pharma Co., Ltd.
New P1 trial • Diabetes • Metabolic Disorders • Renal Disease • Type 2 Diabetes Mellitus
1 to 7
Of
7
Go to page
1